The race to drug the full spectrum of oncogenic RAS mutations intensifies with D3 Bio's quiet but substantial $108M venture financing. While the investor syndicate remains undisclosed, the capital's destination is clear: advancing D3-001, a potentially best-in-class covalent inhibitor of the KRAS G12D mutation. This target, prevalent in pancreatic, colorectal, and non-small cell lung cancers, has lagged behind the G12C mutation commercially pioneered by Amgen's Lumakras and Mirati's Krazati. D3-001's preclinical profile suggests high potency and selectivity, with the Series B proceeds earmarked for an imminent Phase 1/2 trial in G12D-mutant solid tumors. The funding also supports earlier-stage pipeline programs, including a G12V inhibitor, aiming to build a comprehensive RAS franchise.
The sheer size of this round, absent marquee investor names, signals sophisticated backers are placing a concentrated bet on D3 Bio's structural biology platform and its ability to crack the next major KRAS isoform. It reflects a calculated risk that G12D, despite being a more crowded space than G12C was at its inception, represents a larger patient population and a multi-billion dollar opportunity for the first mover with a superior drug. This deal underscores a pivotal shift in oncology venture: the bar for 'undruggable' target platforms is now clinical proof-of-concept, not just compelling biochemistry. Capital is consolidating around a handful of teams with the tools to deliver it, leaving me-too RAS programs out in the cold.